Fig. 1 · Structure
Documents & Downloads
Lefradafiban
GP IIb/IIIa Receptor Antagonist
Lefradafiban is an orally active glycoprotein IIb/IIIa receptor antagonist. It is metabolized to its active form, Fradafiban, which inhibits platelet aggregation by blocking the GP IIb/IIIa receptor. This compound is primarily utilized in research focused on thrombosis, cardiovascular diseases, and platelet function studies.
In Stock
Free Aliquoting for Your Order
Tell us your preferred amount per vial. We’ll confirm the options.
Specifications
| Manufacturer | Adooq Bioscience |
|---|---|
| Actions | Antagonist |
| CAS Number | 149503-79-7 |
| Applications | GP IIb/IIIa Receptor Antagonist |
| Formula | C23H25N3O6 |
| Molecular Weight | 439.46 |
| SMILES | N=C(C(C=C1)=CC=C1C(C=C2)=CC=C2OC[C@H]3NC([C@H](CC(OC)=O)C3)=O)NC(OC)=O |
Storage & Solubility
In Vitro Solubility
Reported Solubility
No reported solubility data are available for this product.
Preparing Stock Solutions
| Concentration | |
|---|---|
Values use four significant digits. Prepare to the final solution volume; this is not the volume of solvent to add.
Stock preparation is unavailable for this product molecular weight.
Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.
Storage
Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.